Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 18 Show results per page	View Search Criteria \| Help With Results

Last Modified: 11/14/2008 First Published: 2/21/2003


1.		Phase I/II Study of Melanoma Vaccine Comprising Autologous Dendritic Cells Pulsed With Tumor Antigen Peptides With or Without Ex Vivo CD40- Ligand and Denileukin Diftitox in Patients With HLA-A1- and/or HLA-A2.1-Positive Stage III or IV Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				over 18				Other				ERLANGEN-ONTAK EU-20246, NCT00056134

Last Modified: 10/28/2008 First Published: 1/16/2007


2.		Phase I/II Study of Denileukin Diftitox in Patients With Refractory Advanced Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Biomarker/Laboratory analysis, Treatment				Active				18 and over				NCI				UWCC-6308 UWCC-05-6951-A, NCT00425672


3.		Study of ONTAK in Patients With B-Cell Chronic Lymphocytic Leukemia (CLL)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Pharmaceutical / Industry				L4389-34 NCT00055146

Last Modified: 7/28/2006 First Published: 8/24/2005


4.		Phase II Study of Denileukin Diftitox in Patients With Tac-Expressing HTLV-1-Associated Adult T-Cell Leukemia/Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				NCI				NCI-05-C-0185 NCI-P6591, NCT00138190

Last Modified: 7/17/2007 First Published: 10/7/2005


5.		Phase II Study of Denileukin Diftitox in Patients With Stage III or IV Ovarian Epithelial or Primary Peritoneal Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Other				TULCC-TC-01-4 TULCC-C0307, NCT00238186


6.		Phase II Trial of Ontak With Metastatic Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Other				076.06 NCT00299689


7.		A Pilot Study to Determine the Safety of the Combination of Ontak in Combination With CHOP in Peripheral T-Cell Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Other				0507000369 NCT00337987

First Published: 4/6/2007


8.		Phase II Study of Rituximab and Denileukin Diftitox in Patients With Previously Untreated Stage III or IV Follicular B-Cell Non-Hodgkin's Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Biomarker/Laboratory analysis, Treatment				Active				18 and over				NCI				NCCTG-N0682 N0682, NCT00460109


9.		Vaccination Plus Ontak in Patients With Metastatic Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Other				15232B NCT00515528


10.		Treatment of Peripheral T-Cell Lymphoma With Aggressive Induction Chemotherapy Followed by Autologous Stem Cell Transplant Using Denileukin Diftitox (Ontak)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 to 70				Other				UC-PTCL-ONTAK NCT00632827

Select All on One Page


					1 2 Next >

| | | | | | | |

A Service of the National Cancer Institute